July 6, 2012 -- Radiopharmaceutical provider IBA Molecular has found a buyer for a Canadian PET radiopharmacy.
The sale was prompted by IBA's decision to form IBA Molecular through a joint venture deal with SK Capital Partners. For legal reasons, IBA Molecular operations in Canada could not be included in the new venture.
In its place, IBA has signed a letter of intent to sell its shares in Pharmalogic PET Services of Montreal for approximately 10.9 million euros ($13.9 million U.S.) to a Canadian private equity firm.
The transaction could close within the next 60 days and result in a profit of approximately 9 million euros ($11.2 million U.S.) for IBA.
IBA agrees to first proton therapy installation in Europe, June 29, 2012
IBA secures new radiopharmacy contracts, June 5, 2012
IBA installs cyclotron, proton system in Italy, May 8, 2012
IBA Molecular deal finalized, April 2, 2012
IBA posts 2011 gains but net loss, March 19, 2012